Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of mRNA-1345 RSV vaccine in high-risk children and adolescents
2024-000502-15Phase 2
- Sponsor
- Moderna Inc
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of RNA-100-AR02 in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Moderna Inc. Primary endpoint: Solicited local and systemic adverse reactions.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-000502-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000502-15.